Moderna’s COVID-19 Trial Delayed: Should Investors Worry?

Moderna (NASDAQ: MRNA) was one of the first companies to kick off a phase 1 clinical trial for its investigational COVID-19 vaccine, mRNA-1273. The trial tested the vaccine's safety, immunogenicity (ability to cause immune system response), and reactogenicity (possible side effects). After getting the green light from the U.S. Food and Drug Administration (FDA), Moderna started a phase 2 trial for mRNA-1273 in May. This trial will test the safety, immunogenicity, and reactogenicity of the vaccine in a pool of 600 healthy participants.